The global biomaterials market size was estimated at USD 106.5 billion in 2019 and is expected to register a CAGR of 15.9% over the forecast period. Rising prevalence of musculoskeletal and chronic skeletal medical conditions are expected to boost the demand for biomaterial-based implants, thereby augmenting the market growth. The demand for orthopedic implants is also rising owing to the increasing geriatric population, at an increased risk of osteoarthritis, osteoporosis, and other musculoskeletal disorders.
Technological advancements have made biomaterials more versatile and have increased their utility in various fields of healthcare, such as bioengineering and tissue engineering. The advent of smart biomaterials that interact with biological systems for several biomedical applications, such as from transport of bioactive molecules to cellular functioning of the engineered functional tissues, drives the revenue generation in this market.
Companies are embracing the ongoing developments in novel drug delivery approaches for the controlled release of drugs, thus fueling the market growth. For instance, in January 2019, DSM Biomedical partnered with ProMed Pharma to leverage its biomedical biomaterials with ProMed’s micro molding and extrusion capabilities to create novel controlled-release drug implants and combination devices.
The porous-coated and fully or partially porous orthopedic implants have gained immense popularity in recent years. This is because the porous structures reduce the elastic modulus and stimulate bone growth around the implant. Powder metallurgy, 3-D printing, and additive manufacturing are some of the potential techniques to manufacture porous metallic and ceramic implants.
Growing demand for smart biomaterials that produce and transfer bioelectric signals similar to native tissues for accurate physiological functions, is expected to surge the market growth. Piezoelectric scaffolds are smart materials that play a significant role in tissue engineering. They stimulate the signaling pathways and consequently improve tissue regeneration at the impaired site.
The polymer product segment dominated the market in terms of revenue in 2019 and is expected to continue leading throughout the forecast period owing to the wide range of product applications. The wide availability of biopolymers and advanced polymers for bio-resorbable tissue fixation and other orthopedic applications is also expected to accelerate the revenue generation of the segment.
Polymeric biomaterials are one of the cornerstones of tissue engineering. Ongoing progression in technologies, such as micromanufacturing, surface modification, drug delivery, nanotechnology, and high-throughput screening, play an integral role in broadening the polymeric material usage in the tissue engineering field.
Natural biomaterials are anticipated to witness a lucrative growth rate during the forecast period, owing to various benefits of the product over synthetic biomaterials in terms of biodegradability, biocompatibility, and remodeling. Due to these advantages, they are increasingly used to replace or restore the structure and function of damaged organs or tissues.
The orthopedic application segment has dominated the biomaterials market in terms of revenue generation in 2019. Increasing adoption of metallic biomaterials in orthopedic applications due to their high load-bearing capacity is one of the factors driving the segment growth. Besides, continuous developments for the introduction of advanced orthopedic implants by market vendors are also expected to propel the revenue generation.
For instance, in November 2019, DiFusion Inc. received FDA approval for its Xiphos-ZF spinal interbody device, which is based on a different biomaterial Zfuze, a combination of poly-ether-ether-ketone and titanium. This new biomaterial leads to significant reductions of cytokine markers that cause inflammation and are associated with fibrous tissue formation.
Plastic surgery application is expected to grow at a significant pace in the coming years owing to the increasing number of cosmetic procedures and increased usage of biomaterials in these surgeries. As per the 2019 publication of the International Society of Aesthetic Plastic Surgery, in the U.S., around 4.3 million cosmetic procedures were performed in 2018, which has positively influenced the segment growth.
North America accounted for the largest revenue share in 2019 owing to the initiatives undertaken by several public and private organizations. These include the National Science Foundation and the National Institute of Standards and Technology, which provide knowledge and assistance pertaining to biomaterials usage in biomedical applications. This has resulted in the expansion of biomaterials adoption in this region. Moreover, factors such as favorable government policies and the presence of several major market players in this region have contributed to the regional market share.
Asia Pacific is expected to register the highest CAGR over the forecast period, owing to strategic initiatives adopted by the regional participants to reinforce their presence in local as well as global markets. For instance, in November 2019, a Japan-based company, Mitsubishi Chemical signed an agreement with U.S.-based AdvanSource Biomaterials to acquire their thermoplastic polyurethane elastomer business. This acquisition is expected to the company expand their business footprint globally and capture significant share in the international market.
Prominent companies in the market include Medtronic plc; Evonik Industries AG; Carpenter Technology Corporation; Berkeley Advanced Biomaterials; Invibio Ltd.; Zimmer Biomet Holdings, Inc.; BASF SE; Covalon Technologies Ltd.; Stryker; Johnson & Johnson; Dentsply Sirona; CoorsTek Inc.; Corbion; and Collagen Matrix, Inc.
Key companies are making significant investments to expand their presence and maintain a competitive edge. They are also adopting strategies such as agreements, partnerships, and collaboration models to strengthen their product portfolio. Moreover, key vendors are inclined toward the development of more innovative products to expand their biomaterials offerings.
For instance, in October 2019, Evonik Industries commercially launched its bioresorbable PLA-PEG copolymers that are designed to use in implantable medical devices. This product development improved the biocompatibility, safety, and performance of implantable products used by medical device customers and further strengthened Evonik’s growth.
Report Attribute |
Details |
Market size value in 2020 |
USD 121.1 billion |
Revenue forecast in 2027 |
USD 348.4 billion |
Growth Rate |
CAGR of 15.97% from 2020 to 2027 |
Base year for estimation |
2019 |
Historical data |
2016 - 2018 |
Forecast period |
2020 - 2027 |
Quantitative units |
Revenue in USD Million and CAGR from 2020 to 2027 |
Report coverage |
Revenue forecast; company share; competitive landscape; growth factors and trends |
Segments covered |
Product, application, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
Country scope |
U.S.; Canada; Germany; U.K.; Japan; China; Brazil; Mexico; South Africa |
Key companies profiled |
Medtronic plc; Evonik Industries AG; Carpenter Technology Corporation; Berkeley Advanced Biomaterials; Invibio Ltd.; Zimmer Biomet Holdings, Inc.; BASF SE; Covalon Technologies Ltd.; Stryker; Johnson & Johnson; Dentsply Sirona; CoorsTek Inc.;Corbion; Collagen Matrix, Inc. |
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country; regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at global, regional, & country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2027. For the purpose of this study, Grand View Research has segmented the global biomaterials market
report on the basis of product, application, and region:
Product Outlook (Revenue, USD Million, 2016 - 2027)
Metallic
Natural
Ceramics
Polymers
Application Outlook (Revenue, USD Million, 2016 - 2027)
Cardiovascular
Sensors
Stents
Guidewires
Implantable Cardiac Defibrillators
Pacemakers
Vascular Grafts
Others
Ophthalmology
Synthetic Corneas
Intraocular Lens
Contact Lens
Ocular Tissue Replacement
Others
Dental
Tissue Regeneration Materials
Dental Implants
Bone Grafts & Substitutes
Dental Membranes
Others
Orthopedic
Joint Replacement Biomaterials
Orthobiologics
Bioresorbable Tissue Fixation Products
Viscosupplementation
Spine Biomaterials
Others
Wound Healing
Fracture Healing Device
Adhesion Barrier
Skin Substitutes
Internal Tissue Sealant
Surgical Hemostats
Others
Tissue Engineering
Plastic Surgery
Facial Wrinkle Treatment
Soft Tissue Fillers
Craniofacial Surgery
Bioengineered Skins
Peripheral Nerve Repair
Acellular Dermal Matrices
Others
Neurology
Neural Stem Cell Encapsulation
Shunting Systems
Hydrogel Scaffold For CNS Repair
Cortical Neural Prosthetics
Others
Others
Regional Outlook (Revenue, USD Million, 2016 - 2027)
North America
The U.S.
Canada
Europe
Germany
The U.K.
Asia Pacific
Japan
China
Latin America
Brazil
Mexico
Middle East and Africa (MEA)
South Africa
b. The global biomaterials market size was estimated at USD 106.5 billion in 2019 and is expected to reach USD 121.1 billion in 2020.
b. The global biomaterials market is expected to grow at a compound annual growth rate of 15.97% from 2020 to 2027 to reach USD 348.4 billion by 2027.
b. The polymer product segment dominated the biomaterials market with a share of 40.8% in 2019. The wide availability of biopolymers and advanced polymers for bio-resorbable tissue fixation and other orthopedic applications is expected to accelerate segment revenue generation.
b. Some key players operating in the biomaterials market include Medtronic plc; Evonik Industries AG; Carpenter Technology Corporation; Berkeley Advanced Biomaterials; Invibio Ltd.; Zimmer Biomet Holdings, Inc.; BASF SE; Covalon Technologies Ltd.; Stryker; Johnson & Johnson; Dentsply Sirona; CoorsTek Inc.;Corbion; and Collagen Matrix, Inc.
b. Key factors that are driving the market growth include rising demand as a consequence of accidental injuries & chronic conditions, advances in biomaterials technologies, and expansion in the usage scope of biomaterials.
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.
"The quality of research they have done for us has been excellent."
Biopharmaceutical innovators are at the forefront of the human response to the coronavirus pandemic. A significant number of major biotech firms are in the midst of a race to investigate the Sars-Cov-2 genome and prepare a viable vaccine for the same. As compared to the speed of response to SARS/MERs etc, the biotech entities are investigating SARs-Cov-2 at an unprecedented rate and a considerable amount of funds are being put into the R&D. With multiple candidates in trial, the public and private sectors are anticipated to work in unison for the foreseeable period, until a vaccine is developed for Covid-19. The report will account for Covid19 as a key market contributor.
We value your investment and offer free customization with every report to fulfil your exact research needs.